Studies Examine Ability Of Antiretroviral Maraviroc To Control HIV Viral Loads

According to two studies sponsored by drugmaker Pfizer and published in the New England Journal of Medicine , the antiretroviral drug maraviroc, which is sold as Selzentry by Pfizer, might help control viral loads among HIV-positive people who have shown resistance to other treatments, Reuters reports. The studies were conducted among 1,049 people in Australia, Europe and North America, and all the participants were resistant to three of the six classes of HIV/AIDS drugs that are available. At the study's 48-week mark, at least 42% of the people who took maraviroc once or twice daily with a standard HIV/AIDS drug combination therapy reported viral loads below levels that cause visible damage to the immune system, compared with 18% of the participants who received a placebo along with a standard combination therapy.

For more information visit http://www.medicalnewstoday.com/articles/124255.php